Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opioid Analgesics Risk Management Models Include Stadol NS, Actiq

Executive Summary

An FDA advisory committee will consider whether risk management models used for Bristol-Myers Squibb's Stadol NS, Sanofi-Synthelab's Talwin NX and Cephalon's Actiq should be more generally applied to other opioid analgesics.

You may also be interested in...



Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?

Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14

Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?

Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14

Opioid Analgesic Risk Management Should Not Inhibit Access, Cmte. Says

Risk management plans for opioid analgesics should be modified if it appears the plan inhibits access for the appropriate patient population, FDA's Anesthetic & Life Support Drugs Advisory Committee said

Related Content

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel